What are the stock market, what are the analysts saying about SONN? Are they saying, uhm, RISE still?

The analysts are saying yes, SONN could rise based on the following:

1. **Analyst Ratings**: The most recent analyst rating on SONN stock is a Buy with a $240.00 price target. This suggests that analysts believe the stock has potential for growth from its current trading price.
2. **Price Target Increase**: Chardan Capital has adjusted the price target on Sonnet BioTherapeutics Holdings PT to $240.00 from $2.50, maintaining a Buy rating. This increase in the price target indicates a more positive outlook on the stock.
3. **Strategic Merger and Hyperliquid Treasury**: The merger with Rorschach I LLC and the launch of the Hyperliquid treasury are seen as positive developments that could drive the stock price higher.
4. **Retail Sentiment**: On Stocktwits, retail sentiment around Sonnet is extremely bullish, with message volume staying at extremely high levels. This sentiment could contribute to a rise in the stock price.

In conclusion, based on the analyst ratings, price target increases, strategic developments, and retail sentiment, it is reasonable to believe that SONN could rise in value. However, investors should conduct a thorough analysis of the company's financials and market position before making any investment decisions.